Skip to main content

09-12-2019 | Haematology | Video

ASH 2019 | ELEVATE TN: Acalabrutinib outperforms chlorambucil in CLL

Jeff Sharman reports findings highlighting improved survival outcomes for treatment-naïve patients with chronic lymphocytic leukaemia taking acalabrutinib versus chlorambucil alongside obinutuzumab (4:13).

Funding for independent interviews at ASH 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits